Cayuga Biotech
Cayuga Biotech is developing first-in-class therapeutics that harness the body’s innate ability to stop bleeding using a proprietary biomimetic approach. The company targets life-threatening noncompressible hemorrhage and coagulation dysfunction, including bleeding caused by irreversible platelet inhibitors like Plavix® (clopidogrel), across surgical, trauma, and obstetric settings.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Current treatments do not adequately treat noncompressible hemorrhage and many types of coagulation dysfunction, such as that caused by irreversible platelet inhibitors like Plavix® (clopidogrel). This results in delayed hemostatic control, and every second counts for survival. Hemorrhage is a top underlying cause of death after surgery, childbirth, trauma, and related to the use of blood thinners.
Solution
Cayuga Biotech is developing first-in-class therapeutics that harness the body’s innate ability to stop bleeding using a proprietary biomimetic approach. The company was founded to address significant unmet need in hemorrhage control, targeting life-threatening situations where current treatments are inadequate. Its science enables a novel way to tackle hemorrhage, distinguishing it from conventional approaches that focus on clotting factor replacement or other mechanisms. By mimicking the body's natural hemostatic processes, Cayuga aims to achieve faster and more effective control of bleeding across a range of clinical scenarios, including noncompressible hemorrhage and bleeding disorders.
Target Audience
The primary customers are healthcare providers and hospital systems managing life-threatening hemorrhage in surgical, trauma, obstetric, and anticoagulation-related settings, as well as patients with inherited bleeding disorders who have unmet therapeutic needs.
Features
- Proprietary biomimetic science that leverages the body's innate hemostatic mechanisms for a novel therapeutic approach
- Targets noncompressible hemorrhage, a major cause of death where current interventions are often ineffective
- Addresses coagulation dysfunction induced by irreversible platelet inhibitors like Plavix® (clopidogrel)
- Designed for rapid hemostatic control where delayed treatment can impact survival
- Focused on multiple high-acuity settings including surgery, childbirth, and trauma